AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00314743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT00314743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Study NCT03501472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-only PWL
Study NCT00710021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight
Study NCT00710021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: 86% microcrystalline cellulose, 14% fumed silica by weight
Study NCT03501472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-emot PWL
Study NCT03501472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-emot PWL
Study NCT03501472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: immed posttest
Study NCT03501472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delay posttest
Study NCT00143910 — intervention group
Intervention type: OTHER
Intervention: observation
Study NCT01308944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study NCT03858699 — intervention group
Intervention type: OTHER
Intervention: Recording of electroencephalographic (EEG) data
Description: Non-invasive brain activity will be measured with electroencephalography (EEG). EEG uses scalp sensors to monitor the brain's electrical activity. EEG sensors are placed on the scalp and passively record neural activity with high time resolution.
Study NCT00038012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombopoietin
Study NCT00038012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-pheresis
Study NCT00038012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02350985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol was given in a flexible dose between 40 mg to 160 mg with an escalating fashion starting at 40 mg PO AM for one week and followed by 40 mg AM and 40 mg PM for a total dose up to 160 mg daily
Study NCT02350985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine treatment was followed as: 37.5 mg qhs for two weeks and followed 75 mg qhs with an escalating dose with 2 weeks periods up to 150 mg daily
Study NCT01725490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
Study NCT01725490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
Study NCT01011673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
Study NCT01011673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: ketorolac 30mg IVSS
Study NCT04650243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Description: The two experimental groups will receive reduced dosage of UDCA at 250mg bid and 250mg qd respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be five years.
Study NCT04650243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ursodeoxycholic acid
Description: The two experimental groups will receive reduced dosage of UDCA at 250mg bid and 250mg qd respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be five years.
Study NCT00998335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-acting bedtime insulin detemir (Levemir)
Description: This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
Study NCT00998335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin detemir and pre-meal insulin aspart.
Description: This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.
Study NCT00557947 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: intradermal and topical suturing
Study NCT00557947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabond Protape (Prineo)
Description: cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
Study NCT04230291 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Verbal consultation
Description: Verbal consultation only without written information before receiving written action plan
Study NCT04230291 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Written Action Plan
Description: Written handout of treatment plan and disease management strategies
Study NCT04230291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Action Plan
Description: Written handout of treatment plan and disease management strategies
Study NCT04532554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Recombinant growth hormone will be used
Study NCT04532554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection with the same amount
Study NCT03861208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: foods with high satiation (high protein and high fiber foods) are offered to modify children's hunger and fullness ratings postprandial
Study NCT03861208 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual diet
Description: foods representing the usually provided foods at childcare are offered
Study NCT02286986 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cannabidiol
Study NCT01825733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Description: Ramosetron 0.3 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
Study NCT01825733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron
Description: palonosetrno 0.075 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
Study NCT02250092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: 10 tDCS/CIMT Sessions
Study NCT02250092 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT02641496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-OSA
Description: CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
Study NCT02641496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
Study NCT02589561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote fitting
Description: remote fitting of hearing aids
Study NCT02589561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote fitting
Description: remote fitting of hearing aids
Study NCT02589561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face to face fitting
Description: face to face fitting of hearing aids
Study NCT02589561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face to face fitting
Description: face to face fitting of hearing aids
Study NCT02096315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: Intravenous infusion
Study NCT01417650 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: In this group, the 890 nm diode laser (Mustang 2000+, Russia) will be applied with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
Study NCT01417650 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Low level laser therapy
Description: In this group, the low level laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
Study NCT01911598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU will be administered as per schedule specified in the respective arm.
Study NCT01911598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as per schedule specified in the respective arm.
Study NCT01911598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as per schedule specified in the respective arm.
Study NCT01911598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A will be administered as per schedule specified in the respective arms.
Study NCT01911598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per schedule specified in the respective arm.
Study NCT03686332 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Arm A: Atezolizumab and Radiotherapy
Description: patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment.
Study NCT03686332 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Arm B: Atezolizumab
Description: patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
Study NCT01026285 — intervention group
Intervention type: DRUG
Intervention: Risperidone Long-Acting injectable or oral antipsychotics
Description: According to label
Study NCT00541398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of guideline
Description: Outreach visits with interactive education for health staff
Study NCT00701532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil and PET (brain imaging)
Description: duration 90 days
Study NCT00701532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: duration 90 days
Study NCT03404453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Difficult airway incidence and prediction
Description: Paediatric patients scheduled for surgery under general anaesthesia will be examined and a set up of airway prediction tests will be performed to predict the possibility of difficult airway
Study NCT01681888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sanger EMG Biofeedback Device
Study NCT03166410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cell injection
Study NCT02167737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedside Decision Aid
Description: This group will have an initial FES and VES screening completed in the ED, the TUG test and Chair 30-Second Stand test, and the participant's risk of falling evaluated using our Bedside Decision worksheets. A study team member explains what subjects can do to decrease their risk of falling and discuss what mobility goals are the most important to them.~Participants will receive a follow-up telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history.
Study NCT02167737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: This group will also have an initial FES and VES screening completed in the ED and the same two mobility tests (TUG and Chair 30-Second Stand). Study staff will advise subjects on how to take action to prevent falls and give them a brochure, What YOU Can Do to Prevent Falls, from the CDC's STEADI Tool Kit for Health Care Providers.~Participants will receive a telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history.
Study NCT03981562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: Patients will take an oral vitamin D supplement once a day for 6 months.
Study NCT03981562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients will take a placebo oral tablet once a day for 6 months.
Study NCT02750280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MatriStem® [Urinary Bladder Matrix (UBM)]
Description: Porcine derived urinary bladder extracellular matrix
Study NCT02750280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex® [Silicone foam dressing]
Description: primary wound dressing
Study NCT01182194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinyl Estradiol (Gianvi®)
Description: 3 mg/0.02 mg Tablets
Study NCT01182194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YAZ®
Description: 3 mg/0.02 mg Tablets
Study NCT00760968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-783 and methotrexate
Description: TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
Study NCT00760968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
Study NCT04014491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scapula control exercise
Description: To perform arm elevation in the scapular plane, subjects will be first asked to correct scapular resting posture in sitting with EMG biofeedback. Then the subjects will be instructed to do elevation in the scapular plane, side lying external rotation and dynamic hug plus with control of the scapula by EMG feedback and verbal cues
Study NCT04014491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scapular strengthening exercise
Description: The subjects in the scapular strengthening group will be asked to perform these three exercises the same as scapula control group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
Study NCT04014491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03732599 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Deep Anterior Keratoplasty (S-DALK)
Description: Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
Study NCT03732599 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IE-DALK (femtosecond)
Description: Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
Study NCT03301896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHC165
Description: LHC165 intratumoral injection
Study NCT03301896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 infusion
Study NCT03975959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: QMRP questionnaire
Description: a single consultation for test and questionnaires for a duration of 20 minutes
Study NCT00287703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsating Electro-Magnetic Fields
Description: 5 days a week for 5 weeks 30 minutes
Study NCT00287703 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pulsating Electro-Magnetic Fields sham
Description: sham PEMF
Study NCT04750785 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.
Study NCT02938091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: Typical Western diet
Study NCT02938091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Description: Traditional Caribbean Hispanic diet
Study NCT03306017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Three venous blood sampling before the left ventricular assist device implantation and 1 and 2 months after implantation in ambulatory patients.
Study NCT04918446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-POSE
Description: Tablet based education and videos on opioid safety, use, and storage/disposal of the drug.
Study NCT04918446 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Printed instruction sheets on prescribed opioid.
Study NCT02618642 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Irradiations of the biceps brachii muscle with PILER light. The participants were randomized into 4 groups: group v - no filter/ group x - red filter/ group y - blue filter/ group z - placebo.
Description: Biceps brachii examination was carried out before (examination 1) and after (examination 2) a series of 10 PILER light treatments. It included a traditional electrodiagnostic examination and the assessment of the pressure pain threshold (PPT).~The electrodiagnostic examination of the muscle was performed using the unipolar stimulation method from the direct motor point. The passive electrode (6 cm x 6 cm) was attached to the side of the distal part of the forearm, and the distal edge of the electrode was adjacent to the proximal edge of the ulnar styloid process. The examination was performed with a Multitronic MT3 electrotherapy apparatus set.~PPT at the direct motor point was determined using an algometer (Algometer commander TM ITECH Medical Industries). A head with a rubber jacket with a surface area of 0.5 cm2 was used to cause pressure pain. Pressure was exerted until the participant reported pain, at which time the force (lbs) marked by the algometer was recorded.
Study NCT02618642 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Irradiations of the biceps brachii muscle with PILER light. The participants were randomized into 4 groups: group v - no filter/ group x - red filter/ group y - blue filter/ group z - placebo.
Description: Biceps brachii examination was carried out before (examination 1) and after (examination 2) a series of 10 PILER light treatments. It included a traditional electrodiagnostic examination and the assessment of the pressure pain threshold (PPT).~The electrodiagnostic examination of the muscle was performed using the unipolar stimulation method from the direct motor point. The passive electrode (6 cm x 6 cm) was attached to the side of the distal part of the forearm, and the distal edge of the electrode was adjacent to the proximal edge of the ulnar styloid process. The examination was performed with a Multitronic MT3 electrotherapy apparatus set.~PPT at the direct motor point was determined using an algometer (Algometer commander TM ITECH Medical Industries). A head with a rubber jacket with a surface area of 0.5 cm2 was used to cause pressure pain. Pressure was exerted until the participant reported pain, at which time the force (lbs) marked by the algometer was recorded.
Study NCT02070224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Serum and urine samples collections
Description: Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)
Study NCT02070224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Imaging (x-rays and MRI)
Description: MRI will be done at baseline and 12 month and x-rays will be done at baseline
Study NCT02962167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Measles Virus
Description: Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor
Study NCT02962167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Measles Virus Lumbar Puncture
Description: Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
Study NCT03661203 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus group
Description: Focus group for qualitative group only
Study NCT04179006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)
Description: 3 pieces per day
Study NCT03661203 — intervention group
Intervention type: BEHAVIORAL
Intervention: Individual interview
Description: Individual interview for qualitative group only
Study NCT03661203 — intervention group
Intervention type: BEHAVIORAL
Intervention: online self questionnaire
Description: online self questionnaire
Study NCT04179006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)
Description: 3 pieces per day